Outsourced Pharma White Papers

41. Can You Afford Not To Outsource Buffer Preparation? 2/6/2020

    The decision whether or not to outsource buffer preparation is not clear-cut, but provides an opportunity to balance risk with reward. This column examines the benefits of outsourcing.

42. Developing A Scalable Process For Adenovirus Manufacturing 4/2/2019

    To address the growing need for speed and efficiency in viral vector manufacturing, GE developed a process for adenovirus manufacturing that not only meets regulatory requirements but is also scalable.

43. Beyond COVID-19: Localization Can Strengthen Supply Chains 5/8/2020

    The coronavirus pandemic has already changed the way industry looks at localization and forming resilient supply chain capabilities. In the current climate, not having local capabilities could shutter your business.

44. Efficient Cleaning-In-Place Methods For Protein-Based Antibody Affinity Chromatography Resins 10/2/2018

    This whitepaper discusses cleaning of affinity resins intended for use in the purification of monoclonal antibodies and antibody fragments.

45. Biotech's Mirrored Universe: Predictive Engineering and Digital Twinning 7/8/2020

    The biotechnology industry now can harness advanced engineering techniques that have helped save astronauts, save energy, and save countless millions of dollars.

46. Embedding Your Drug Strategy Within A Solid Foundation For Success 3/24/2020

    This white paper looks at the set of trends influencing pharmaceutical development and manufacturing strategy today, and how these drivers are influencing new business models with outsourced partners. 

47. Synthesizing Success: Six Principles For Getting Pharmaceutical Development Right From The Start 4/7/2020

    As pharmaceutical industry faces pressure to bring new drugs to market more quickly and at minimal cost, pharmaceutical and biotechnology companies are increasingly outsourcing various parts of the drug development and manufacturing process. This white paper highlights six key points that pharmaceutical and biotechnology companies should keep in mind when looking to select the ideal partner to synthesize an API for them—and ensure their drug development process stays on the path to success.

48. Overview Of A Scale-Up Of A Cell-Based Influenza Virus Production Process Using Single-Use Bioprocessing Equipment 8/3/2018

    This paper includes a discussion on vaccine processes, followed by a case study on the scale-up of upstream and downstream processes for the production of a cell-based live attenuated influenza virus using single-use ReadyToProcess technology.

49. Off-Site Storage Of Biological Specimens And Biologics For Risk Mitigation 2/11/2019

    Choosing an offsite storage facility means asking the right questions to determine if the storage provider has the appropriate risk mitigation infrastructure in place, beginning with a realistic threat assessment.

50. Cold Chain Qualification: 5 Questions You Must Ask When Shipping Biologics 2/11/2019

    Organizations recognize the growing need for control of the entire cold chain as the changing global scenario requires highly efficient processes and flexibility.